1
|
Mallard C, Ferriero DM, Vexler ZS. Immune-Neurovascular Interactions in Experimental Perinatal and Childhood Arterial Ischemic Stroke. Stroke 2024; 55:506-518. [PMID: 38252757 DOI: 10.1161/strokeaha.123.043399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2024]
Abstract
Emerging clinical and preclinical data have demonstrated that the pathophysiology of arterial ischemic stroke in the adult, neonates, and children share similar mechanisms that regulate brain damage but also have distinct molecular signatures and involved cellular pathways due to the maturational stage of the central nervous system and the immune system at the time of the insult. In this review, we discuss similarities and differences identified thus far in rodent models of 2 different diseases-neonatal (perinatal) and childhood arterial ischemic stroke. In particular, we review acquired knowledge of the role of resident and peripheral immune populations in modulating outcomes in models of perinatal and childhood arterial ischemic stroke and the most recent and relevant findings in relation to the immune-neurovascular crosstalk, and how the influence of inflammatory mediators is dependent on specific brain maturation stages. Finally, we discuss the current state of treatments geared toward age-appropriate therapies that signal via the immune-neurovascular interaction and consider sex differences to achieve successful translation.
Collapse
Affiliation(s)
- Carina Mallard
- Department of Physiology, Institute of Neuroscience and Physiology, University of Gothenburg, Sweden (C.M.)
| | - Donna M Ferriero
- Department of Pediatrics, UCSF, San Francisco, CA (D.M.F.)
- Department of Neurology, UCSF, Weill Institute for Neurosciences, San Francisco, CA (D.M.F., Z.S.V.)
| | - Zinaida S Vexler
- Department of Neurology, UCSF, Weill Institute for Neurosciences, San Francisco, CA (D.M.F., Z.S.V.)
| |
Collapse
|
2
|
CD36 neutralisation blunts TLR2-IRF7 but not IRF3 pathway in neonatal mouse brain and immature human microglia following innate immune challenge. Sci Rep 2023; 13:2304. [PMID: 36759676 PMCID: PMC9911392 DOI: 10.1038/s41598-023-29423-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Accepted: 02/03/2023] [Indexed: 02/11/2023] Open
Abstract
Innate immune response in neonatal brain is associated with a robust microglial activation and induction of Toll-like Receptors (TLRs). To date, the role of the scavenger receptor CD36 in TLRs modulation, particularly TLR2 signaling, has been well established in adult brain. However, the crosstalk between TLR4, TLR2 and CD36 and its immunogenic influence in the neonatal brain remains unclear. In this study, using a CD36 blocking antibody (anti-CD36) at post-natal day 8, we evaluated the response of neonates to systemic endotoxin (lipopolysaccharide; LPS) challenge. We visualized the TLR2 response by bioluminescence imaging using the transgenic mouse model bearing the dual reporter system luciferase/green fluorescent protein under transcriptional control of a murine TLR2 promoter. The anti-CD36 treatment modified the LPS induced inflammatory profile in neonatal brains, causing a significant decrease in inflammatory cytokine levels and the TLR2 and TLR3 mediated signalling.The interferon regulatory factor 3 (IRF3) pathway remained unaffected. Treatment of the LPS-challenged human immature microglia with anti-CD36 induced a marked decrease in TLR2/TLR3 expression levels while TLR4 and IRF3 expression was not affected, suggesting the shared CD36 regulatory mechanisms in human and mouse microglia. Collectively, our results indicate that blocking CD36 alters LPS-induced inflammatory profile of mouse and human microglia, suggesting its role in fine-tuning of neuroinflammation.
Collapse
|
3
|
Ziqing Z, Yunpeng L, Yiqi L, Yang W. Friends or foes: The mononuclear phagocyte system in ischemic stroke. Brain Pathol 2023; 33:e13151. [PMID: 36755470 PMCID: PMC10041168 DOI: 10.1111/bpa.13151] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Accepted: 01/09/2023] [Indexed: 02/10/2023] Open
Abstract
Ischemic stroke (IS) is a major cause of disability and death in adults, and the immune response plays an indispensable role in its pathological process. After the onset of IS, an inflammatory storm, with the infiltration and mobilization of the mononuclear phagocyte system (MPS), is triggered in the brain. Microglia are rapidly activated in situ, followed by waves of circulating monocytes into the ischemic area. Activated microglia and monocytes/macrophages are mainly distributed in the peri-infarct area. These cells have similar morphology and functions, such as secreting cytokines and phagocytosis. Previously, the presence of the MPS was considered a marker of an exacerbated inflammatory response that contributes to brain damage. However, recent studies have suggested a rather complicated role of the MPS in IS. Here, we reviewed articles focusing on various functions of the MPS among different phases of IS, including recruitment, polarization, phagocytosis, angiogenesis, and interaction with other types of cells. Moreover, due to the characteristics of the MPS, we also noted clinical research addressing alterations in the MPS as potential biomarkers for IS patients for the purposes of predicting prognosis and developing novel therapeutic strategies.
Collapse
Affiliation(s)
- Zhang Ziqing
- Department of Neurosurgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
| | - Liu Yunpeng
- Department of Neurosurgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
| | - Liu Yiqi
- Department of Neurosurgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
| | - Wang Yang
- Department of Neurosurgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
| |
Collapse
|
4
|
Roseborough AD, Myers SJ, Khazaee R, Zhu Y, Zhao L, Iorio E, Elahi FM, Pasternak SH, Whitehead SN. Plasma derived extracellular vesicle biomarkers of microglia activation in an experimental stroke model. J Neuroinflammation 2023; 20:20. [PMID: 36721258 PMCID: PMC9890769 DOI: 10.1186/s12974-023-02708-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Accepted: 01/27/2023] [Indexed: 02/02/2023] Open
Abstract
Chronic microglia activation post-stroke is associated with worse neurological and cognitive outcomes. However, measurement of microglia activation in vivo is currently limited. Plasma derived extracellular vesicles (EVs) are cell-specific indicators that may allow for non-invasive measurement of microglia phenotype. The aim of this study was to identify activation-state specific microglia EVs (MEVs) in vitro followed by validation in an experimental stroke model. Following pro-inflammatory activation, MEVs contain the microglia protein TMEM119 alongside increased expression of the Toll-like receptor 4 co-receptor CD14. Immunoprecipitation followed by fluorescent nanoparticle tracking analysis (ONI Nanoimager) was used to confirm the isolation of TMEM119+/CD14+ EVs from rat plasma. Electron microscopy confirmed that TMEM119 and CD14 localize to the MEV membrane. To model ischemia, plasma was collected from 3-month wildtype Fischer344 rats prior to, 7 and 28 days after endothelin-1 or saline injection into the dorsal right striatum. Fluorescently labelled MEVs were directly measured in the plasma using nanoflow cytometry (Apogee A60 Microplus). We report a significant increase in circulating TMEM119+/CD14+ EVs 28-days post-stroke in comparison to baseline levels and saline-injected rats, which correlated weakly with stroke volume. TMEM119+/MHC-II+ EVs were also increased post-stroke in comparison to baseline and saline-injected animals. This study is the first to describe an EV biomarker of activated microglia detected directly in plasma following stroke and represents a future tool for the measurement of microglia activity in vivo.
Collapse
Affiliation(s)
- A. D. Roseborough
- grid.39381.300000 0004 1936 8884Vulnerable Brain Laboratory, Department of Anatomy and Cell Biology, The Schulich School of Medicine and Dentistry, The University of Western Ontario, 458 Medical Sciences Building, ON N6A 3K London, Canada
| | - S. J. Myers
- grid.39381.300000 0004 1936 8884Vulnerable Brain Laboratory, Department of Anatomy and Cell Biology, The Schulich School of Medicine and Dentistry, The University of Western Ontario, 458 Medical Sciences Building, ON N6A 3K London, Canada
| | - R. Khazaee
- grid.39381.300000 0004 1936 8884Biotron Integrated Microscopy Facility, The University of Western Ontario, London, ON Canada ,grid.39381.300000 0004 1936 8884Deparment of Biology, The University of Western Ontario, London, ON Canada
| | - Y. Zhu
- grid.39381.300000 0004 1936 8884Vulnerable Brain Laboratory, Department of Anatomy and Cell Biology, The Schulich School of Medicine and Dentistry, The University of Western Ontario, 458 Medical Sciences Building, ON N6A 3K London, Canada
| | - L. Zhao
- grid.39381.300000 0004 1936 8884Vulnerable Brain Laboratory, Department of Anatomy and Cell Biology, The Schulich School of Medicine and Dentistry, The University of Western Ontario, 458 Medical Sciences Building, ON N6A 3K London, Canada
| | - E. Iorio
- grid.266102.10000 0001 2297 6811Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA USA
| | - F. M. Elahi
- grid.266102.10000 0001 2297 6811Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA USA ,grid.59734.3c0000 0001 0670 2351Icahn School of Medicine at Mount Sinai, New York, USA ,grid.39381.300000 0004 1936 8884Department of Clinical Neurological Sciences, The Schulich School of Medicine and Dentistry, The University of Western Ontario, ON London, Canada
| | - S. H. Pasternak
- grid.59734.3c0000 0001 0670 2351Icahn School of Medicine at Mount Sinai, New York, USA ,grid.39381.300000 0004 1936 8884Department of Clinical Neurological Sciences, The Schulich School of Medicine and Dentistry, The University of Western Ontario, ON London, Canada ,grid.39381.300000 0004 1936 8884Robarts Research Institute, The Schulich School of Medicine and Dentistry, The University of Western Ontario, ON London, Canada
| | - S. N. Whitehead
- grid.39381.300000 0004 1936 8884Vulnerable Brain Laboratory, Department of Anatomy and Cell Biology, The Schulich School of Medicine and Dentistry, The University of Western Ontario, 458 Medical Sciences Building, ON N6A 3K London, Canada
| |
Collapse
|
5
|
Ha GH, Kim EJ, Park JS, Kim JE, Nam H, Yeon JY, Lee SH, Lee K, Kim CK, Joo KM. JAK2/STAT3 pathway mediates neuroprotective and pro-angiogenic treatment effects of adult human neural stem cells in middle cerebral artery occlusion stroke animal models. Aging (Albany NY) 2022; 14:8944-8969. [PMID: 36446389 PMCID: PMC9740376 DOI: 10.18632/aging.204410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Accepted: 11/17/2022] [Indexed: 12/03/2022]
Abstract
Mismatches between pre-clinical and clinical results of stem cell therapeutics for ischemic stroke limit their clinical applicability. To overcome these discrepancies, precise planning of pre-clinical experiments that can be translated to clinical trials and the scientific elucidation of treatment mechanisms is important. In this study, adult human neural stem cells (ahNSCs) derived from temporal lobe surgical samples were used (to avoid ethical and safety issues), and their therapeutic effects on ischemic stroke were examined using middle cerebral artery occlusion animal models. 5 × 105 ahNSCs was directly injected into the lateral ventricle of contralateral brain hemispheres of immune suppressed rat stroke models at the subacute phase of stroke. Compared with the mock-treated group, ahNSCs reduced brain tissue atrophy and neurological sensorimotor and memory functional loss. Tissue analysis demonstrated that the significant therapeutic effects were mediated by the neuroprotective and pro-angiogenic activities of ahNSCs, which preserved neurons in ischemic brain areas and decreased reactive astrogliosis and microglial activation. The neuroprotective and pro-angiogenic effects of ahNSCs were validated in in vitro stroke models and were induced by paracrine factors excreted by ahNSCs. When the JAK2/STAT3 signaling pathway was inhibited by a specific inhibitor, AG490, the paracrine neuroprotective and pro-angiogenic effects of ahNSCs were reversed. This pre-clinical study that closely simulated clinical settings and provided treatment mechanisms of ahNSCs for ischemic stroke may aid the development of protocols for subsequent clinical trials of ahNSCs and the realization of clinically available stem cell therapeutics for ischemic stroke.
Collapse
Affiliation(s)
- Geun-Hyoung Ha
- Medical Innovation Technology Inc. (MEDINNO Inc.), Seoul 08513, South Korea
| | - Eun Ji Kim
- Medical Innovation Technology Inc. (MEDINNO Inc.), Seoul 08513, South Korea
| | - Jee Soo Park
- Department of Anatomy and Cell Biology, Sungkyunkwan University School of Medicine, Suwon 16419, South Korea
| | - Ji Eun Kim
- Medical Innovation Technology Inc. (MEDINNO Inc.), Seoul 08513, South Korea
| | - Hyun Nam
- Medical Innovation Technology Inc. (MEDINNO Inc.), Seoul 08513, South Korea,Stem Cell and Regenerative Medicine Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul 06351, South Korea,Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, South Korea
| | - Je Young Yeon
- Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, South Korea
| | - Sun-Ho Lee
- Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, South Korea,Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 06351, South Korea
| | - Kyunghoon Lee
- Department of Anatomy and Cell Biology, Sungkyunkwan University School of Medicine, Suwon 16419, South Korea,Single Cell Network Research Center, Sungkyunkwan University School of Medicine, Suwon 16149, South Korea,Biomedical Institute for Convergence at SKKU (BICS), Sungkyunkwan University, Suwon 16419, South Korea
| | - Chung Kwon Kim
- Medical Innovation Technology Inc. (MEDINNO Inc.), Seoul 08513, South Korea,Biomedical Institute for Convergence at SKKU (BICS), Sungkyunkwan University, Suwon 16419, South Korea
| | - Kyeung Min Joo
- Medical Innovation Technology Inc. (MEDINNO Inc.), Seoul 08513, South Korea,Department of Anatomy and Cell Biology, Sungkyunkwan University School of Medicine, Suwon 16419, South Korea,Stem Cell and Regenerative Medicine Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul 06351, South Korea,Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 06351, South Korea,Single Cell Network Research Center, Sungkyunkwan University School of Medicine, Suwon 16149, South Korea,Biomedical Institute for Convergence at SKKU (BICS), Sungkyunkwan University, Suwon 16419, South Korea
| |
Collapse
|
6
|
Abstract
Stroke remains a significant unmet clinical need with few treatment options that have a very narrow therapeutic window, thereby causing massive mortality and morbidity in the United States and around the world. Accordingly, finding safe and effective novel treatments with a wider therapeutic window stands as an urgent need in stroke. The progressive inflammation that occurs centrally and peripherally after stroke serves as a unique therapeutic target to retard and even halt the secondary cell death. Stem cell therapy represents a potent approach that can diminish inflammation in both the stroke brain and periphery (eg, spleen), advancing a paradigm shift from a traditionally brain-focused therapy to treating stroke as a neurological disorder with a significant peripheral pathology. The purpose of this review article is to highlight the inflammation-mediated secondary cell death that plagues both brain and spleen in stroke and to evaluate the therapeutic potential of stem cell therapy in dampening these inflammatory responses.
Collapse
Affiliation(s)
- Stefan Anthony
- Lake Erie College of Osteopathic Medicine, 5000 Lakewood Ranch Boulevard, Bradenton, FL 34211, USA
| | - Dorothy Cabantan
- Michigan State University College of Osteopathic Medicine, 965 Wilson Rd, East Lansing, MI 48824, USA
| | - Molly Monsour
- Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA
| | - Cesario V. Borlongan
- Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA
| |
Collapse
|
7
|
Beuker C, Strecker JK, Rawal R, Schmidt-Pogoda A, Ruck T, Wiendl H, Klotz L, Schäbitz WR, Sommer CJ, Minnerup H, Meuth SG, Minnerup J. Immune Cell Infiltration into the Brain After Ischemic Stroke in Humans Compared to Mice and Rats: a Systematic Review and Meta-Analysis. Transl Stroke Res 2021; 12:976-990. [PMID: 33496918 PMCID: PMC8557159 DOI: 10.1007/s12975-021-00887-4] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Revised: 12/30/2020] [Accepted: 01/04/2021] [Indexed: 12/14/2022]
Abstract
Although several studies have suggested that anti-inflammatory strategies reduce secondary infarct growth in animal stroke models, clinical studies have not yet demonstrated a clear benefit of immune modulation in patients. Potential reasons include systematic differences of post-ischemic neuroinflammation between humans and rodents. We here performed a systematic review and meta-analysis to summarize and compare the spatial and temporal distribution of immune cell infiltration in human and rodent stroke. Data on spatiotemporal distribution of immune cells (T cells, macrophages, and neutrophils) and infarct volume were extracted. Data from all rodent studies were pooled by means of a random-effect meta-analysis. Overall, 20 human and 188 rodent stroke studies were included in our analyses. In both patients and rodents, the infiltration of macrophages and neutrophils preceded the lymphocytic influx. Macrophages and neutrophils were the predominant immune cells within 72 h after infarction. Although highly heterogeneously across studies, the temporal profile of the poststroke immune response was comparable between patients and rodents. In rodent stroke, the extent of the immune cell infiltration depended on the duration and location of vessel occlusion and on the species. The density of infiltrating immune cells correlated with the infarct volume. In summary, we provide the first systematic analysis and comparison of human and rodent post-ischemic neuroinflammation. Our data suggest that the inflammatory response in rodent stroke models is comparable to that in patients with stroke. However, the overall heterogeneity of the post-ischemic immune response might contribute to the translational failure in stroke research.
Collapse
Affiliation(s)
- Carolin Beuker
- Department of Neurology with Institute of Translational Neurology, University of Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149, Münster, Germany
| | - Jan-Kolja Strecker
- Department of Neurology with Institute of Translational Neurology, University of Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149, Münster, Germany
| | - Rajesh Rawal
- Institute of Epidemiology and Social Medicine, University of Münster, Albert-Schweitzer-Campus 1, Münster, Germany
| | - Antje Schmidt-Pogoda
- Department of Neurology with Institute of Translational Neurology, University of Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149, Münster, Germany
| | - Tobias Ruck
- Department of Neurology with Institute of Translational Neurology, University of Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149, Münster, Germany
| | - Heinz Wiendl
- Department of Neurology with Institute of Translational Neurology, University of Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149, Münster, Germany
| | - Luisa Klotz
- Department of Neurology with Institute of Translational Neurology, University of Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149, Münster, Germany
| | | | - Clemens J Sommer
- Institute of Neuropathology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
| | - Heike Minnerup
- Institute of Epidemiology and Social Medicine, University of Münster, Albert-Schweitzer-Campus 1, Münster, Germany
| | - Sven G Meuth
- Department of Neurology with Institute of Translational Neurology, University of Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149, Münster, Germany
| | - Jens Minnerup
- Department of Neurology with Institute of Translational Neurology, University of Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149, Münster, Germany.
| |
Collapse
|
8
|
Pase MP, Himali JJ, Beiser AS, DeCarli C, McGrath ER, Satizabal CL, Aparicio HJ, Adams HHH, Reiner AP, Longstreth WT, Fornage M, Tracy RP, Lopez O, Psaty BM, Levy D, Seshadri S, Bis JC. Association of CD14 with incident dementia and markers of brain aging and injury. Neurology 2020; 94:e254-e266. [PMID: 31818907 PMCID: PMC7108812 DOI: 10.1212/wnl.0000000000008682] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Accepted: 07/18/2019] [Indexed: 12/20/2022] Open
Abstract
OBJECTIVE To test the hypothesis that the inflammatory marker plasma soluble CD14 (sCD14) associates with incident dementia and related endophenotypes in 2 community-based cohorts. METHODS Our samples included the prospective community-based Framingham Heart Study (FHS) and Cardiovascular Health Study (CHS) cohorts. Plasma sCD14 was measured at baseline and related to the incidence of dementia, domains of cognitive function, and MRI-defined brain volumes. Follow-up for dementia occurred over a mean of 10 years (SD 4) in the FHS and a mean of 6 years (SD 3) in the CHS. RESULTS We studied 1,588 participants from the FHS (mean age 69 ± 6 years, 47% male, 131 incident events) and 3,129 participants from the CHS (mean age 72 ± 5 years, 41% male, 724 incident events) for the risk of incident dementia. Meta-analysis across the 2 cohorts showed that each SD unit increase in sCD14 was associated with a 12% increase in the risk of incident dementia (95% confidence interval 1.03-1.23; p = 0.01) following adjustments for age, sex, APOE ε4 status, and vascular risk factors. Higher levels of sCD14 were associated with various cognitive and MRI markers of accelerated brain aging in both cohorts and with a greater progression of brain atrophy and a decline in executive function in the FHS. CONCLUSION sCD14 is an inflammatory marker related to brain atrophy, cognitive decline, and incident dementia.
Collapse
Affiliation(s)
- Matthew P Pase
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA
| | - Jayandra J Himali
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA
| | - Alexa S Beiser
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA
| | - Charles DeCarli
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA
| | - Emer R McGrath
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA
| | - Claudia L Satizabal
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA
| | - Hugo J Aparicio
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA
| | - Hieab H H Adams
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA
| | - Alexander P Reiner
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA
| | - W T Longstreth
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA
| | - Myriam Fornage
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA
| | - Russell P Tracy
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA
| | - Oscar Lopez
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA
| | - Bruce M Psaty
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA
| | - Daniel Levy
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA
| | - Sudha Seshadri
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
| | - Joshua C Bis
- From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA
| |
Collapse
|
9
|
Hermann JK, Capadona JR. Understanding the Role of Innate Immunity in the Response to Intracortical Microelectrodes. Crit Rev Biomed Eng 2019; 46:341-367. [PMID: 30806249 DOI: 10.1615/critrevbiomedeng.2018027166] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Intracortical microelectrodes exhibit enormous potential for researching the nervous system, steering assistive devices and functional electrode stimulation systems for severely paralyzed individuals, and augmenting the brain with computing power. Unfortunately, intracortical microelectrodes often fail to consistently record signals over clinically useful periods. Biological mechanisms, such as the foreign body response to intracortical microelectrodes and self-perpetuating neuroinflammatory cascades, contribute to the inconsistencies and decline in recording performance. Unfortunately, few studies have directly correlated microelectrode performance with the neuroinflammatory response to the implanted devices. However, of those select studies that have, the role of the innate immune system remains among the most likely links capable of corroborating the results of different studies, across laboratories. Therefore, the overall goal of this review is to highlight the role of innate immunity signaling in the foreign body response to intracortical microelectrodes and hypothesize as to appropriate strategies that may become the most relevant in enabling brain-dwelling electrodes of any geometry, or location, for a range of clinical applications.
Collapse
Affiliation(s)
- John K Hermann
- Department of Biomedical Engineering, Case Western Reserve University, 2071 Martin Luther King Jr. Drive, Wickenden Bldg, Cleveland, OH 44106; Advanced Platform Technology Center, Rehabilitation Research and Development, Louis Stokes Cleveland VA Medical Center, 10701 East Blvd. Mail Stop 151 AW/APT, Cleveland, OH 44106-1702
| | - Jeffrey R Capadona
- Department of Biomedical Engineering, Case Western Reserve University, 2071 Martin Luther King Jr. Drive, Wickenden Bldg, Cleveland, OH 44106; Advanced Platform Technology Center, Rehabilitation Research and Development, Louis Stokes Cleveland VA Medical Center, 10701 East Blvd. Mail Stop 151 AW/APT, Cleveland, OH 44106-1702
| |
Collapse
|
10
|
Bidirectional Transcriptome Analysis of Rat Bone Marrow-Derived Mesenchymal Stem Cells and Activated Microglia in an In Vitro Coculture System. Stem Cells Int 2018; 2018:6126413. [PMID: 30151012 PMCID: PMC6087576 DOI: 10.1155/2018/6126413] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Revised: 05/15/2018] [Accepted: 05/24/2018] [Indexed: 02/07/2023] Open
Abstract
Microglia contribute to the regulation of neuroinflammation and play an important role in the pathogenesis of brain diseases. Thus, regulation of neuroinflammation triggered by activated microglia in brain diseases has become a promising curative strategy. Bone marrow-derived mesenchymal stem cells (BM-MSCs) have been shown to have therapeutic effects, resulting from the regulation of inflammatory conditions in the brain. In this study, we investigated differential gene expression in rat BM-MSCs (rBM-MSCs) that were cocultured with lipopolysaccharide- (LPS-) stimulated primary rat microglia using microarray analysis and evaluated the functional relationships through Ingenuity Pathway Analysis (IPA). We also evaluated the effects of rBM-MSC on LPS-stimulated microglia using a reverse coculture system and the same conditions of the transcriptomic analysis. In the transcriptome of rBM-MSCs, 67 genes were differentially expressed, which were highly related with migration of cells, compared to control. The prediction of the gene network using IPA and experimental validation showed that LPS-stimulated primary rat microglia increase the migration of rBM-MSCs. Reversely, expression patterns of the transcriptome in LPS-stimulated primary rat microglia were changed when cocultured with rBM-MSCs. Our results showed that 65 genes were changed, which were highly related with inflammatory response, compared to absence of rBM-MSCs. In the same way with the aforementioned, the prediction of the gene network and experimental validation showed that rBM-MSCs decrease the inflammatory response of LPS-stimulated primary rat microglia. Our data indicate that LPS-stimulated microglia increase the migration of rBM-MSCs and that rBM-MSCs reduce the inflammatory activity in LPS-stimulated microglia. The results of this study show complex mechanisms underlying the interaction between rBM-MSCs and activated microglia and may be helpful for the development of stem cell-based strategies for brain diseases.
Collapse
|
11
|
Abd-Nikfarjam B, Nassiri-Asl M, Hajiaghayi M, Naserpour Farivar T. Role of Chicoric Acid and 13-Cis Retinoic Acid in Mycobacterium tuberculosis Infection Control by Human U937 Macrophage. Arch Immunol Ther Exp (Warsz) 2018; 66:399-406. [DOI: 10.1007/s00005-018-0511-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Accepted: 02/22/2018] [Indexed: 11/24/2022]
|
12
|
Mugge L, Mansour TR, Krafcik B, Mazur T, Floyd-Bradstock T, Medhkour A. Immunological, vascular, metabolic, and autonomic changes seen with aging possible implications for poor outcomes in the elderly following decompressive hemicraniectomy for malignant MCA stroke: a critical review. J Neurosurg Sci 2018. [PMID: 29527887 DOI: 10.23736/s0390-5616.18.04207-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
INTRODUCTION Stroke is one of the leading causes of mortality and morbidity worldwide and requires rapid and intensive treatment to prevent adverse outcomes. Decompressive hemicraniectomy stands as the gold standard for surgical resolution of the intracranial swelling which accompanies cerebral infarction; however, the benefits of this procedure are not as well achieved in the elderly (age >65 years) compared to the younger population. EVIDENCE ACQUISITION This is a critical review performed on all available literature relating to middle cerebral artery (MCA) stroke in the elderly with emphasis on articles examining causality of adverse outcomes in this group over younger populations. Utilizing PRISMA guidelines, we initially identified 1462 articles. EVIDENCE SYNTHESIS After screening, four clear areas of physiological change associated with aging were identified and expounded upon as they relate to MCA stroke. These four areas include: immunological, autonomic, mitochondrial, and vascular changes. Elderly patients have a decreased and declining capacity to regulate the inflammation that develops postinfarction and this contributes to adverse outcomes from a neurological stand point. Additionally, aging decreases the ability of elderly patients to regulate their autonomic system resulting in aberrant blood pressures systemically post infarction. With age, the mitochondrial response to ischemia is exaggerated and causes greater local damage in elderly patients compared to younger populations. Finally, there are numerous vascular changes that occur with age including accumulation of homocysteine and atherosclerosis which together contributed to decreased structural integrity of the vasculature in the elderly and render decreased support to the recovery process post infarction. CONCLUSIONS We conclude that physiological changes inherent in the aging process serve to intensify adverse outcomes that are commonly associated with strokes in the elderly. Identification and subsequent minimization of these risk factors could allow for more effective management of elderly patients, post stroke, and promote better clinical outcomes.
Collapse
Affiliation(s)
- Luke Mugge
- Division of Neurological Surgery, Department of Surgery, University of Toledo Medical Center, Toledo, OH, USA
| | - Tarek R Mansour
- Division of Neurological Surgery, Department of Surgery, University of Toledo Medical Center, Toledo, OH, USA
| | - Brianna Krafcik
- Division of Neurological Surgery, Department of Surgery, University of Toledo Medical Center, Toledo, OH, USA
| | - Travis Mazur
- Division of Neurological Surgery, Department of Surgery, University of Toledo Medical Center, Toledo, OH, USA
| | - Tonya Floyd-Bradstock
- Interprofessional Immersive Simulation Center, University of Toledo Medical Center, Toledo, OH, USA
| | - Azedine Medhkour
- Division of Neurological Surgery, Department of Surgery, University of Toledo Medical Center, Toledo, OH, USA -
| |
Collapse
|
13
|
Wei Y, Chen J, Hu Y, Lu W, Zhang X, Wang R, Chu K. Rosmarinic Acid Mitigates Lipopolysaccharide-Induced Neuroinflammatory Responses through the Inhibition of TLR4 and CD14 Expression and NF-κB and NLRP3 Inflammasome Activation. Inflammation 2018; 41:732-740. [PMID: 29318480 DOI: 10.1007/s10753-017-0728-9] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The excessive activation of microglia plays a key role in the pathogenesis of neurodegenerative diseases. The neuroprotective properties of rosmarinic acid have been reported in a variety of disease models both in vitro and in vivo; however, the mechanism underlying its anti-neuroinflammatory activity has not been clearly elucidated. In the present study, we evaluated the anti-inflammatory effects of rosmarinic acid in conditions of neuroinflammatory injury in vitro and in vivo. The results indicated that rosmarinic acid reduced the expression of CD11b, a marker of microglia and macrophages, in the brain and dramatically inhibited the levels of inflammatory cytokines and mediators, such as TNFα, IL-6, IL-1β, COX-2, and iNOS, in a dose-dependent manner both in vitro and in vivo. Consistent with these results, the expression levels of TLR4 and CD14 and the phosphorylation of JNK were also reduced. Further study showed that rosmarinic acid suppresses the activation of the NF-κB pathway and NLRP3 inflammasome, which may contribute to its anti-inflammatory effects. These results suggest that rosmarinic acid significantly reduced TLR4 and CD14 expression and NF-κB and NLRP3 inflammasome activation, which is involved in anti-neuroinflammation.
Collapse
Affiliation(s)
- Yicong Wei
- Centre of Biomedical Research & Development, Fujian University of Traditional Chinese Medicine, No. 1 Huatou Road, Minhou Shangjie, Fuzhou, China.
| | - Jianxiong Chen
- Centre of Biomedical Research & Development, Fujian University of Traditional Chinese Medicine, No. 1 Huatou Road, Minhou Shangjie, Fuzhou, China
| | - Yonghong Hu
- Centre of Biomedical Research & Development, Fujian University of Traditional Chinese Medicine, No. 1 Huatou Road, Minhou Shangjie, Fuzhou, China
| | - Wei Lu
- Centre of Biomedical Research & Development, Fujian University of Traditional Chinese Medicine, No. 1 Huatou Road, Minhou Shangjie, Fuzhou, China
| | - Xiaoqin Zhang
- Centre of Biomedical Research & Development, Fujian University of Traditional Chinese Medicine, No. 1 Huatou Road, Minhou Shangjie, Fuzhou, China
| | - Ruiguo Wang
- Centre of Biomedical Research & Development, Fujian University of Traditional Chinese Medicine, No. 1 Huatou Road, Minhou Shangjie, Fuzhou, China
| | - Kedan Chu
- Centre of Biomedical Research & Development, Fujian University of Traditional Chinese Medicine, No. 1 Huatou Road, Minhou Shangjie, Fuzhou, China
| |
Collapse
|
14
|
Tanaka M, Ishihara Y, Mizuno S, Ishida A, Vogel CF, Tsuji M, Yamazaki T, Itoh K. Progression of vasogenic edema induced by activated microglia under permanent middle cerebral artery occlusion. Biochem Biophys Res Commun 2018; 496:582-587. [PMID: 29353043 DOI: 10.1016/j.bbrc.2018.01.094] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2017] [Accepted: 01/14/2018] [Indexed: 12/11/2022]
Abstract
Brain edema is a severe complication that accompanies ischemic stroke. Increasing evidence shows that inflammatory cytokines impair tight junctions of the blood-brain barrier, suggesting the involvement of microglia in brain edema. In this study, we examined the role of microglia in the progression of ischemic brain edema using mice with permanent middle cerebral artery occlusion. The intensity of T2-weighted imaging (T2WI) in the cerebral cortex and the striatum was elevated 3 h after occlusion and spread to peripheral regions of the ischemic hemisphere. Merged images of 2,3,5-triphenyl tetrazolium chloride staining and T2WI revealed the exact vasogenic edema region, which spread from the ischemic core to outside the ischemic region. Microglia were strongly activated in the ischemic region 3 h after occlusion and, notably, activated microglia were observed in the non-ischemic region 24 h after occlusion. Pretreatment with minocycline, an inhibitor of microglial activation clearly suppressed not only vasogenic edema but also infarct formation. We demonstrated in this study that vasogenic edema spreads from the ischemic core to the peripheral region, which can be elicited, at least in part, by microglial activation induced by ischemia.
Collapse
Affiliation(s)
- Miki Tanaka
- Laboratory of Molecular Brain Science, Graduate School of Integrated Arts and Sciences, Hiroshima University, Hiroshima, 739-8521, Japan; Laboratory for Pharmacotherapy and Experimental Neurology, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Kagawa, 769-2193, Japan
| | - Yasuhiro Ishihara
- Laboratory of Molecular Brain Science, Graduate School of Integrated Arts and Sciences, Hiroshima University, Hiroshima, 739-8521, Japan; Center for Health and the Environment, University of California, Davis, Davis, CA, 95616, USA.
| | - Shodo Mizuno
- Laboratory for Pharmacotherapy and Experimental Neurology, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Kagawa, 769-2193, Japan; Department of Pharmaceutical Service, Shikoku Medical Center of Children and Adults, National Hospital Organization, Kagawa, 765-8501, Japan
| | - Atsuhiko Ishida
- Laboratory of Molecular Brain Science, Graduate School of Integrated Arts and Sciences, Hiroshima University, Hiroshima, 739-8521, Japan
| | - Christoph F Vogel
- Center for Health and the Environment, University of California, Davis, Davis, CA, 95616, USA; Department of Environmental Toxicology, University of California, Davis, Davis, CA, 95616, USA
| | - Mayumi Tsuji
- Department of Environmental Health, University of Occupational and Environmental Health, Fukuoka, 807-8555, Japan
| | - Takeshi Yamazaki
- Laboratory of Molecular Brain Science, Graduate School of Integrated Arts and Sciences, Hiroshima University, Hiroshima, 739-8521, Japan
| | - Kouichi Itoh
- Laboratory for Pharmacotherapy and Experimental Neurology, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Kagawa, 769-2193, Japan
| |
Collapse
|
15
|
Chen YJ, Nguyen HM, Maezawa I, Jin LW, Wulff H. Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke. Ann Clin Transl Neurol 2017; 5:147-161. [PMID: 29468176 PMCID: PMC5817832 DOI: 10.1002/acn3.513] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Revised: 11/10/2017] [Accepted: 11/20/2017] [Indexed: 12/26/2022] Open
Abstract
Objective Inhibitors of the voltage‐gated K+ channel Kv1.3 are currently in development as immunomodulators for the treatment of autoimmune diseases. As Kv1.3 is also expressed on microglia and has been shown to be specifically up‐regulated on “M1‐like” microglia, we here tested the therapeutic hypothesis that the brain‐penetrant small‐molecule Kv1.3‐inhibitor PAP‐1 reduces secondary inflammatory damage after ischemia/reperfusion. Methods We studied microglial Kv1.3 expression using electrophysiology and immunohistochemistry, and evaluated PAP‐1 in hypoxia‐exposed organotypic hippocampal slices and in middle cerebral artery occlusion (MCAO) with 8 days of reperfusion in both adult male C57BL/6J mice (60 min MCAO) and adult male Wistar rats (90 min MCAO). In both models, PAP‐1 administration was started 12 h after reperfusion. Results We observed Kv1.3 staining on activated microglia in ischemic infarcts in mice, rats, and humans and found higher Kv1.3 current densities in acutely isolated microglia from the infarcted hemisphere than in microglia isolated from the contralateral hemisphere of MCAO mice. PAP‐1 reduced microglia activation and increased neuronal survival in hypoxia‐exposed hippocampal slices as effectively as minocycline. In mouse MCAO, PAP‐1 dose‐dependently reduced infarct area, improved neurological deficit score, and reduced brain levels of IL‐1β and IFN‐γ without affecting IL‐10 and brain‐derived nerve growth factor (BDNF) levels or inhibiting ongoing phagocytosis. The beneficial effects on infarct area and neurological deficit score were reproduced in rats providing confirmation in a second species. Interpretation Our findings suggest that Kv1.3 constitutes a promising therapeutic target for preferentially inhibiting “M1‐like” inflammatory microglia/macrophage functions in ischemic stroke.
Collapse
Affiliation(s)
- Yi-Je Chen
- Department of Pharmacology University of California Davis 95616 California
| | - Hai M Nguyen
- Department of Pharmacology University of California Davis 95616 California
| | - Izumi Maezawa
- Department of Pathology and Laboratory Medicine University of California Davis, Sacramento 95817 California.,M.I.N.D. Institute University of California Davis 95817 California
| | - Lee-Way Jin
- Department of Pathology and Laboratory Medicine University of California Davis, Sacramento 95817 California.,M.I.N.D. Institute University of California Davis 95817 California
| | - Heike Wulff
- Department of Pharmacology University of California Davis 95616 California
| |
Collapse
|
16
|
Lalancette-Hébert M, Faustino J, Thammisetty SS, Chip S, Vexler ZS, Kriz J. Live imaging of the innate immune response in neonates reveals differential TLR2 dependent activation patterns in sterile inflammation and infection. Brain Behav Immun 2017; 65:312-327. [PMID: 28579520 PMCID: PMC6151183 DOI: 10.1016/j.bbi.2017.05.020] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Revised: 05/31/2017] [Accepted: 05/31/2017] [Indexed: 01/07/2023] Open
Abstract
Activation of microglial cells in response to brain injury and/or immune stimuli is associated with a marked induction of Toll-like receptors (TLRs). While in adult brain, the contribution of individual TLRs, including TLR2, in pathophysiological cascades has been well established, their role and spatial and temporal induction patterns in immature brain are far less understood. To examine whether infectious stimuli and sterile inflammatory stimuli trigger distinct TLR2-mediated innate immune responses, we used three models in postnatal day 9 (P9) mice, a model of infection induced by systemic endotoxin injection and two models of sterile inflammation, intra-cortical IL-1β injection and transient middle cerebral artery occlusion (tMCAO). We took advantage of a transgenic mouse model bearing the dual reporter system luciferase/GFP under transcriptional control of a murine TLR2 promoter (TLR2-luc-GFP) to visualize the TLR2 response in the living neonatal brain and then determined neuroinflammation, microglial activation and leukocyte infiltration. We show that in physiological postnatal brain development the in vivo TLR2-luc signal undergoes a marked ∼30-fold decline and temporal-spatial changes during the second and third postnatal weeks. We then show that while endotoxin robustly induces the in vivo TLR2-luc signal in the living brain and increases levels of several inflammatory cytokines and chemokines, the in vivo TLR2-luc signal is reduced after both IL-1β and tMCAO and the inflammatory response is muted. Immunofluorescence revealed that microglial cells are the predominant source of TLR2 production during postnatal brain development and in all three neonatal models studied. Flow cytometry revealed developmental changes in CD11b+/CD45+ and CD11b+/Ly6C+ cell populations, involvement of cells of the monocyte lineage, but lack of Ly6G+ neutrophils or CD3+ cells in acutely injured neonatal brains. Cumulatively, our results suggest distinct TLR2 induction patterns following PAMP and DAMP - mediated inflammation in immature brain.
Collapse
Affiliation(s)
- Melanie Lalancette-Hébert
- Department of Psychiatry and Neuroscience, Faculty of Medicine, Laval University, Research Center of the IUSMQ, 2601, de la Canardière, Québec, QC G1J 2G3, Canada
| | - Joel Faustino
- Department of Neurology, University of California, San Francisco, San Francisco, CA 94158-0663, USA
| | - Sai Sampath Thammisetty
- Department of Psychiatry and Neuroscience, Faculty of Medicine, Laval University, Research Center of the IUSMQ, 2601, de la Canardière, Québec, QC G1J 2G3, Canada
| | - Sophorn Chip
- Department of Neurology, University of California, San Francisco, San Francisco, CA 94158-0663, USA
| | - Zinaida S Vexler
- Department of Neurology, University of California, San Francisco, San Francisco, CA 94158-0663, USA.
| | - Jasna Kriz
- Department of Psychiatry and Neuroscience, Faculty of Medicine, Laval University, Research Center of the IUSMQ, 2601, de la Canardière, Québec, QC G1J 2G3, Canada.
| |
Collapse
|
17
|
Marcet P, Santos N, Borlongan CV. When friend turns foe: central and peripheral neuroinflammation in central nervous system injury. ACTA ACUST UNITED AC 2017; 4:82-92. [PMID: 29670933 PMCID: PMC5901724 DOI: 10.20517/2347-8659.2017.07] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Injury to the central nervous system (CNS) is common, and though it has been well studied, many aspects of traumatic brain injury (TBI) and stroke are poorly understood. TBI and stroke are two pathologic events that can cause severe, immediate impact to the neurostructure and function of the CNS, which has been recognized recently to be exacerbated by the body’s own immune response. Although the brain damage induced by the initial trauma is most likely unsalvageable, the secondary immunologic deterioration of neural tissue gives ample opportunity for therapeutic strategists seeking to mitigate TBI’s secondary detrimental effects. The purpose of this paper is to highlight the cell death mechanisms associated with CNS injury with special emphasis on inflammation. The authors discuss sources of inflammation, and introduce the role of the spleen in the systemic response to inflammation after CNS injury.
Collapse
Affiliation(s)
- Paul Marcet
- Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, Tampa, FL 33612, USA
| | - Nicole Santos
- Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, Tampa, FL 33612, USA
| | - Cesar V Borlongan
- Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, Tampa, FL 33612, USA
| |
Collapse
|
18
|
Nykjaer CH, Brudek T, Salvesen L, Pakkenberg B. Changes in the cell population in brain white matter in multiple system atrophy. Mov Disord 2017; 32:1074-1082. [PMID: 28394027 DOI: 10.1002/mds.26979] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2016] [Revised: 02/02/2017] [Accepted: 02/25/2017] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND Multiple system atrophy (MSA) is a sporadic progressive neurodegenerative disorder with adult onset and unknown etiology. Clinically it is characterized by autonomic failure, cerebellar ataxia, parkinsonism, and corticospinal dysfunction in any combination and with varying severity. OBJECTIVES AND METHODS To establish the extent of involvement of the white matter in the disease, we have used stereology to quantify the total number of neurons and glial cells (oligodendrocytes, astrocytes, and microglia) in the brains from 10 MSA patients and 11 controls. RESULTS The mean total number of white matter interstitial neurons in the patient brains was 0.5 × 109 (coefficient of variation = standard deviation/mean = 0.37), which was significantly lower than the 1.1 × 109 (0.41) in the control brains (P = .001) and equal to a reduction by ∼50%. The patient brains had a significantly higher number of white matter microglia, 1.5 × 109 (0.47) versus 0.7 × 109 (0.39) microglia in the control subjects (P = .003) and equal to an increase by ∼ 100%. There was no significant difference in mean total numbers of white matter oligodendrocytes and astrocytes between the groups. CONCLUSIONS We found widespread microgliosis without concomitant astrogliosis in brain white matter in MSA patients and demonstrated an absence of significant oligodendrocyte degeneration. The exact role of oligodendrocytes in MSA pathogenesis, including neurodegeneration, remains to be elucidated. © 2017 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Charlotte Havelund Nykjaer
- Research Laboratory for Stereology and Neuroscience, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark
| | - Tomasz Brudek
- Research Laboratory for Stereology and Neuroscience, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark
| | - Lisette Salvesen
- Research Laboratory for Stereology and Neuroscience, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark.,Department of Neurology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark
| | - Bente Pakkenberg
- Research Laboratory for Stereology and Neuroscience, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark.,Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
19
|
Kawabori M, Yenari MA. Inflammatory responses in brain ischemia. Curr Med Chem 2016; 22:1258-77. [PMID: 25666795 DOI: 10.2174/0929867322666150209154036] [Citation(s) in RCA: 190] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2014] [Revised: 10/02/2014] [Accepted: 02/02/2015] [Indexed: 12/20/2022]
Abstract
Brain infarction causes tissue death by ischemia due to occlusion of the cerebral vessels and recent work has shown that post stroke inflammation contributes significantly to the development of ischemic pathology. Because secondary damage by brain inflammation may have a longer therapeutic time window compared to the rescue of primary damage following arterial occlusion, controlling inflammation would be an obvious therapeutic target. A substantial amount of experimentall progress in this area has been made in recent years. However, it is difficult to elucidate the precise mechanisms of the inflammatory responses following ischemic stroke because inflammation is a complex series of interactions between inflammatory cells and molecules, all of which could be either detrimental or beneficial. We review recent advances in neuroinflammation and the modulation of inflammatory signaling pathways in brain ischemia. Potential targets for treatment of ischemic stroke will also be covered. The roles of the immune system and brain damage versus repair will help to clarify how immune modulation may treat stroke.
Collapse
Affiliation(s)
| | - Midori A Yenari
- Dept. of Neurology, University of California, San Francisco and the San Francisco Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA.
| |
Collapse
|
20
|
Velázquez A, Ortega M, Rojas S, González-Oliván FJ, Rodríguez-Baeza A. Widespread microglial activation in patients deceased from traumatic brain injury. Brain Inj 2015; 29:1126-33. [PMID: 26067626 DOI: 10.3109/02699052.2015.1018325] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
PRIMARY OBJECTIVE The role of microglial activation in traumatic brain injury (TBI) has been extensively described in established animal models. In contrast, very few studies have analysed this process in human patients, the majority being focused on the local reaction in the contused parenchyma. In this work, the main objective was the analysis of microglial activation in brain regions distant from the primary lesion. RESEARCH DESIGN Morphological changes of microglia were evaluated in the cerebral cortex of patients deceased from TBI in comparison with control subjects. METHODS AND PROCEDURES Cortical samples from five cases with TBI and 10 controls were evaluated using Ricinus communis lectin histochemistry and conventional Hematoxylin-eosin staining. MAIN OUTCOMES AND RESULTS It was observed that microglial cells from patients with TBI presented shorter and thicker cellular projections compared with controls. Moreover, the percentage of histological area reactive to lectin was statistically higher in samples from subjects with TBI. These signs of microglial activation were observed in all of the analysed cortical areas, thus indicating a generalized effect on the whole cerebral cortex. The results are consistent with previous imaging PET studies performed in living patients with the 11C-PK11195 radiotracer. CONCLUSIONS The findings indicate that TBI induces a widespread activation of brain microglia which affects all cortical areas, including those distant from the contusion site.
Collapse
Affiliation(s)
- Antonio Velázquez
- Departamento de Ciencias Morfológicas, Facultad de Medicina, Universitat Autònoma de Barcelona , Barcelona , Spain and
| | | | | | | | | |
Collapse
|
21
|
Lai W, Zheng Z, Zhang X, Wei Y, Chu K, Brown J, Hong G, Chen L. Salidroside-Mediated Neuroprotection is Associated with Induction of Early Growth Response Genes (Egrs) Across a Wide Therapeutic Window. Neurotox Res 2015; 28:108-21. [PMID: 25911293 DOI: 10.1007/s12640-015-9529-9] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2014] [Revised: 03/26/2015] [Accepted: 04/13/2015] [Indexed: 10/23/2022]
Abstract
Salidroside exhibits anti-inflammatory, anti-oxidative, and anti-apoptotic properties. To identify whether salidroside might be a candidate for treating ischemic stroke, we investigated the effects of salidroside or vehicle, given daily for 6 days, after middle cerebral artery occlusion (MCAO) for 2 h and reperfusion for either 1 or 48 h in rats. Salidroside reduced cerebral infarct volume and significantly improved neurological scores whether started after 1 or 48 h of reperfusion. Microarray analysis showed that 20 % (133/678) of the genes down-regulated by ischemia and 1 h of reperfusion were up-regulated by salidroside, whereas 13 % (105/829) of the genes induced by ischemia-reperfusion were inhibited by salidroside, suggesting that salidroside can reverse effects of ischemia-reperfusion on gene expression. The main enriched functional categories induced by salidroside were genes related to synaptic plasticity, whereas salidroside inhibited genes related to inflammation. Induction of Egr1, Egr2, Egr4, and Arc by salidroside was confirmed by qRT-PCR and western blotting in ischemic brains treated after either 1 or 48 h of reperfusion. The potential protective role of Egr4 in salidroside-mediated neuroprotection was subsequently investigated in CoCl2-treated PC12 cells. Egr4 was dose-dependently induced by salidroside in PC12 cells, and depleting Egr4 with target-specific siRNA increased caspase-3 activity and Bax, but decreased Bcl-xl, which were reversed by salidroside. Finally, we confirmed that salidroside inhibited the Bax/Bcl-xl-related apoptosis after MCAO with reperfusion. In conclusion, salidroside is highly neuroprotective with a wide therapeutic time window after ischemia-reperfusion injury in the rat, and this partially involves induction of Egrs, leading to inhibition of Bax/Bcl-xl-related apoptosis.
Collapse
Affiliation(s)
- Wenfang Lai
- Centre of Biomedical Research & Development, Fujian University of Traditional Chinese Medicine, No. 1 Huatou Road, Minhou Shangjie, Fuzhou, China
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
Microglia are considered the brain's resident immune cell involved in immune defense, immunocompetence, and phagocytosis. They maintain tissue homeostasis within the brain and spinal cord under normal condition and serves as its initial host defense system. However, when the central nervous system (CNS) faces injury, microglia respond through signaling molecules expressed or released by neighboring cells. Microglial responses are dual in nature. They induce a nonspecific immune response that may exacerbate CNS injury, especially in the acute stages, but are also essential to CNS recovery and repair. The full range of microglial mechanisms have yet to be clarified, but there is accumulating knowledge about microglial activation in acute CNS injury. Microglial responses require hours to days to fully develop, and may present a therapeutic target for intervention with a much longer window of opportunity compare to other neurological treatments. The challenge will be to find ways to selectively suppress the deleterious effects of microglial activation without compromising its beneficial functions. This review aims to provide an overview of the recent progress relating on the deleterious and beneficial effect of microglia in the setting of acute CNS injury and the potential therapeutic intervention against microglial activation to CNS injury.
Collapse
Affiliation(s)
- Masahito Kawabori
- Department of Neurology, University of California, San Francisco and the San Francisco Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA, 94121, USA
| | | |
Collapse
|
23
|
Benakis C, Garcia-Bonilla L, Iadecola C, Anrather J. The role of microglia and myeloid immune cells in acute cerebral ischemia. Front Cell Neurosci 2015; 8:461. [PMID: 25642168 PMCID: PMC4294142 DOI: 10.3389/fncel.2014.00461] [Citation(s) in RCA: 147] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2014] [Accepted: 12/18/2014] [Indexed: 01/15/2023] Open
Abstract
The immune response to acute cerebral ischemia is a major contributor to stroke pathobiology. The inflammatory response is characterized by the participation of brain resident cells and peripheral leukocytes. Microglia in the brain and monocytes/neutrophils in the periphery have a prominent role in initiating, sustaining and resolving post-ischemic inflammation. In this review we aim to summarize recent literature concerning the origins, fate and role of microglia, monocytes and neutrophils in models of cerebral ischemia and to discuss their relevance for human stroke.
Collapse
Affiliation(s)
- Corinne Benakis
- Feil Family Brain and Mind Research Institute, Weill Cornell Medical College New York, NY, USA
| | - Lidia Garcia-Bonilla
- Feil Family Brain and Mind Research Institute, Weill Cornell Medical College New York, NY, USA
| | - Costantino Iadecola
- Feil Family Brain and Mind Research Institute, Weill Cornell Medical College New York, NY, USA
| | - Josef Anrather
- Feil Family Brain and Mind Research Institute, Weill Cornell Medical College New York, NY, USA
| |
Collapse
|
24
|
Tobin RP, Mukherjee S, Kain JM, Rogers SK, Henderson SK, Motal HL, Rogers MKN, Shapiro LA. Traumatic brain injury causes selective, CD74-dependent peripheral lymphocyte activation that exacerbates neurodegeneration. Acta Neuropathol Commun 2014; 2:143. [PMID: 25329434 PMCID: PMC4203873 DOI: 10.1186/s40478-014-0143-5] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2014] [Accepted: 09/11/2014] [Indexed: 12/17/2022] Open
Abstract
Introduction Traumatic brain injury (TBI), a significant cause of death and disability, causes, as in any injury, an acute, innate immune response. A key component in the transition between innate and adaptive immunity is the processing and presentation of antigen by professional antigen presenting cells (APCs). Whether an adaptive immune response to brain injury is beneficial or detrimental is not known. Current efforts to understand the contribution of the immune system after TBI have focused on neuroinflammation and brain-infiltrating immune cells. Here, we characterize and target TBI-induced expansion of peripheral immune cells that may act as potential APCs. Because MHC Class II-associated invariant peptide (CLIP) is important for antigen processing and presentation, we engineered a competitive antagonist (CAP) for CLIP, and tested the hypothesis that peptide competition could reverse or prevent neurodegeneration after TBI. Results We show that after fluid percussion injury (FPI), peripheral splenic lymphocytes, including CD4+ and CD8+ T cells, regulatory T cells (Tregs), and γδ T cells, are increased in number within 24 hours after FPI. These increases were reversed by CAP treatment and this antagonism of CLIP also reduced neuroinflammation and neurodegeneration after TBI. Using a mouse deficient for the precursor of CLIP, CD74, we observed decreased peripheral lymphocyte activation, decreased neurodegeneration, and a significantly smaller lesion size following TBI. Conclusion Taken together, the data support the hypothesis that neurodegeneration following TBI is dependent upon antigen processing and presentation that requires CD74. Electronic supplementary material The online version of this article (doi:10.1186/s40478-014-0143-5) contains supplementary material, which is available to authorized users.
Collapse
|
25
|
Lujia Y, Xin L, Shiquan W, Yu C, Shuzhuo Z, Hong Z. Ceftriaxone pretreatment protects rats against cerebral ischemic injury by attenuating microglial activation-induced IL-1β expression. Int J Neurosci 2014; 124:657-65. [PMID: 24985046 DOI: 10.3109/00207454.2013.856009] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND Although the neuroprotective effect of ceftriaxone (CTX) has been reported, the underlying mechanisms are still uncertain. In this study, we investigated if rats recover better from CTX pretreatment against cerebral ischemia by inhibiting the inflammatory response. METHODS Rats were pretreated with CTX (200 mg/kg, 1/day, i.p.) for 5 d. At 24 h after the end of the last CTX pretreatment, focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO) for 120 min in male Sprague Dawley rats. The neurological deficit scores (NDS) and infarct volumes were evaluated. Microglia cells were observed by immunofluorescence staining and IL-1β was assayed by ELISA and Western Blot. RESULTS The results showed that CTX pretreatment improved the neurological deficit scores and decreased the infarct volumes 24 h after reperfusion. The activation of microglia cells was reduced and the expression of IL-1β was partially inhibited 24 h after reperfusion. CONCLUSION These findings demonstrate that CTX pretreatment may provide a neuroprotective effect against transient cerebral ischemic injury, partially inhibit in microglial activation and reduce the expression of IL-1β.
Collapse
Affiliation(s)
- Yang Lujia
- 1Department of Anesthesiology, Chinese PLA General Hospital , Beijing , China
| | | | | | | | | | | |
Collapse
|
26
|
Hjalmarsson C, Bjerke M, Andersson B, Blennow K, Zetterberg H, Aberg ND, Olsson B, Eckerström C, Bokemark L, Wallin A. Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. J Cent Nerv Syst Dis 2014; 6:51-8. [PMID: 24932109 PMCID: PMC4039292 DOI: 10.4137/jcnsd.s13821] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2013] [Revised: 03/09/2014] [Accepted: 03/12/2014] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND Cerebral ischemia promotes morphological reactions of the neurons, astrocytes, oligodendrocytes, and microglia in experimental studies. Our aim was to examine the profile of CSF (cerebrospinal fluid) biomarkers and their relation to stroke severity and degree of white matter lesions (WML). METHODS A total of 20 patients (mean age 76 years) were included within 5–10 days after acute ischemic stroke (AIS) onset. Stroke severity was assessed using NIHSS (National Institute of Health stroke scale). The age-related white matter changes (ARWMC) scale was used to evaluate the extent of WML on CT-scans. The concentrations of specific CSF biomarkers were analyzed. RESULTS Patients with AIS had significantly higher levels of NFL (neurofilament, light), T-tau, myelin basic protein (MBP), YKL-40, and glial fibrillary acidic protein (GFAP) compared with controls; T-Tau, MBP, GFAP, and YKL-40 correlated with clinical stroke severity, whereas NFL correlated with severity of WML (tested by Mann–Whitney test). CONCLUSIONS Several CSF biomarkers increase in AIS, and they correlate to clinical stroke severity. However, only NFL was found to be a marker of degree of WML.
Collapse
Affiliation(s)
- Clara Hjalmarsson
- The Stroke Unit, Department of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Maria Bjerke
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, The Sahlgrenska Academy, Gothenburg, Sweden
| | - Björn Andersson
- The Stroke Unit, Department of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Kaj Blennow
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, The Sahlgrenska Academy, Gothenburg, Sweden
| | - Henrik Zetterberg
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, The Sahlgrenska Academy, Gothenburg, Sweden. ; UCL Institute of Neurology, Queen Square, London, UK
| | - N David Aberg
- The Stroke Unit, Department of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Bob Olsson
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, The Sahlgrenska Academy, Gothenburg, Sweden
| | - Carl Eckerström
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, The Sahlgrenska Academy, Gothenburg, Sweden
| | - Lena Bokemark
- The Stroke Unit, Department of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Anders Wallin
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, The Sahlgrenska Academy, Gothenburg, Sweden
| |
Collapse
|
27
|
Tarassishin L, Suh HS, Lee SC. LPS and IL-1 differentially activate mouse and human astrocytes: role of CD14. Glia 2014; 62:999-1013. [PMID: 24659539 DOI: 10.1002/glia.22657] [Citation(s) in RCA: 145] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Revised: 02/04/2014] [Accepted: 02/25/2014] [Indexed: 12/31/2022]
Abstract
Treatment of cultures with toll-like receptor (TLR) ligands or cytokines has become a popular approach to investigate astrocyte neuroinflammatory responses and to simulate the neural environment in various CNS disorders. However, despite much effort, the mechanism of astrocyte activation such as their responses to the TLR ligands and IL-1 remain highly debated. We compared highly pure primary mouse and human astrocyte cultures in their ability to produce proinflammatory mediators (termed "A1") and immunoregulatory mediators (termed "A2") in response to LPS, poly IC, and IL-1 stimulation. In human astrocytes, IL-1 induced both A1 and A2 responses, poly IC induced mostly A2, and LPS induced neither. In mouse astrocytes, LPS induced mostly an A1-predominant response, poly IC induced both A1 and A2, and IL-1 neither. In addition, mouse astrocytes produce abundant IL-1 protein, whereas human astrocytes did not, despite robust IL-1 mRNA expression. Of the TLR4 receptor complex proteins, human astrocytes expressed TLR4 and MD2 but not CD14, whereas mouse astrocytes expressed all three. Mouse astrocyte CD14 (cell-associated and soluble) was potently upregulated by LPS. Silencing TLR4 or CD14 by siRNA suppressed LPS responses in mouse astrocytes. In vivo, astrocytes in LPS-injected mouse brains also expressed CD14. Our results show striking differences between human and mouse astrocytes in the use of TLR/IL-1R and subsequent downstream signaling and immune activation. IL-1 translational block in human astrocytes may be a built-in mechanism to prevent autocrine and paracrine cell activation and neuroinflammation. These results have important implications for translational research of human CNS diseases.
Collapse
Affiliation(s)
- Leonid Tarassishin
- Department of Pathology, Albert Einstein College of Medicine, Bronx, New York, 10461
| | | | | |
Collapse
|
28
|
Vogelgesang A, Becker KJ, Dressel A. Immunological consequences of ischemic stroke. Acta Neurol Scand 2014; 129:1-12. [PMID: 23848237 DOI: 10.1111/ane.12165] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/05/2013] [Indexed: 12/24/2022]
Abstract
The treatment of ischemic stroke is one of the great challenges in modern neurology. The localization and the size of the infarct determine the long-term disability of stroke survivors. Recent observations have revealed that stroke also alters the function of the immune system and vice versa: At the site of the infarct, a local inflammatory response develops that enhances brain lesion development. In experimental stroke, proof-of-concept studies confirm that inhibition of this immune response reduces lesion volume and improves outcome. In the peripheral blood of stroke patients, though, lymphocytopenia and monocyte dysfunction develop. These changes reflect a clinically relevant impairment of bacterial defense mechanisms because they are associated with an enhanced risk to acquire post-stroke infections. Stress hormones have been identified as important mediators of stroke-induced immune suppression. The pharmacological inhibition of beta adrenergic receptors, but not the inhibition of steroids, is effective in reducing infection and improving clinical outcome in experimental stroke; catecholamine release therefore appears causally related to stroke-induced immune suppression. Strong evidence supports the hypothesis that these immune alterations impact the clinical course of stroke patients. Thus, the development of new therapeutic strategies targeted to alter the immunological consequences of stroke appears promising. However, to date, the beneficial effects seen in experimental stroke have not been successfully translated into a clinical trial. This brief review summarizes the current understanding of the immunological consequences of ischemic stroke. Finally, we propose a concept that links the peripheral immune suppression with the development of local inflammation.
Collapse
Affiliation(s)
- A. Vogelgesang
- Universitiy Medicine; Institute of Immunology and Transfusion Medicine; Greifswald Germany
| | - K. J. Becker
- University of Washington School of Medicine; Harborview Medical Center; Seattle WA USA
| | - A. Dressel
- Section of Neuroimmunology; Department of Neurology, University Medicine Greifswald; Greifswald Germany
| |
Collapse
|
29
|
Abstract
Reperfusion of ischemic brain can reduce injury and improve outcome, but secondary injury due to inflammatory mechanisms limits the efficacy and time window of such treatments for stroke. This review summarizes the cellular and molecular basis of inflammation in ischemic injury as well as possible therapeutic strategies.
Collapse
Affiliation(s)
- Muzamil Ahmad
- Geriatric Research Educational and Clinical Center (00-GR-H), V.A. Pittsburgh Healthcare System, 7180 Highland Drive, Pittsburgh, PA 15206, USA; Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA
| | | |
Collapse
|
30
|
Li WA, Moore-Langston S, Chakraborty T, Rafols JA, Conti AC, Ding Y. Hyperglycemia in stroke and possible treatments. Neurol Res 2013; 35:479-91. [PMID: 23622737 DOI: 10.1179/1743132813y.0000000209] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Hyperglycemia affects approximately one-third of acute ischemic stroke patients and is associated with poor clinical outcomes. In experimental and clinical stroke studies, hyperglycemia has been shown to be detrimental to the penumbral tissue for several reasons. First, hyperglycemia exacerbates both calcium imbalance and the accumulation of reactive oxygen species (ROS) in neurons, leading to increased apoptosis. Second, hyperglycemia fuels anaerobic energy production, causing lactic acidosis, which further stresses neurons in the penumbral regions. Third, hyperglycemia decreases blood perfusion after ischemic stroke by lowering the availability of nitric oxide (NO), which is a crucial mediator of vasodilation. Lastly, hyperglycemia intensifies the inflammatory response after stroke, causing edema, and hemorrhage through disruption of the blood brain barrier and degradation of white matter, which leads to a worsening of functional outcomes. Many neuroprotective treatments addressing hyperglycemia in stroke have been implemented in the past decade. Early clinical use of insulin provided mixed results due to insufficiently controlled glucose levels and heterogeneity of patient population. Recently, however, the latest Stroke Hyperglycemia Insulin Network Effort trial has addressed the shortcomings of insulin therapy. While glucagon-like protein-1 administration, hyperbaric oxygen preconditioning, and ethanol therapy appear promising, these treatments remain in their infancy and more research is needed to better understand the mechanisms underlying hyperglycemia-induced injuries. Elucidation of these mechanistic pathways could lead to the development of rational treatments that reduce hyperglycemia-associated injuries and improve functional outcomes for ischemic stroke patients.
Collapse
Affiliation(s)
- William A Li
- Department of Neurological Surgery, Wayne State University School of Medicine, Detroit, MI, USA
| | | | | | | | | | | |
Collapse
|
31
|
Zhou M, Wang CM, Yang WL, Wang P. Microglial CD14 activated by iNOS contributes to neuroinflammation in cerebral ischemia. Brain Res 2013; 1506:105-14. [PMID: 23416151 DOI: 10.1016/j.brainres.2013.02.010] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2012] [Revised: 01/24/2013] [Accepted: 02/06/2013] [Indexed: 10/27/2022]
Abstract
Stroke is one of the most frequent causes of death and disability worldwide. Cerebral ischemia is the major insult of stroke and induces acute inflammation by triggering excessive production of proinflammatory cytokines, leading to the exacerbation of primary brain damage. Toll-like receptor (TLR)- and nitric oxide-mediated signaling pathways have been identified under ischemic stress. However, the interaction between these two pathways in controlling proinflammatory cytokines has not been well addressed during cerebral ischemia. Adult male C57BL/6 mice were subjected to middle cerebral artery occlusion (MCAO) for stroke induction. The MCAO procedure resulted in a significant infarct in the brain after 24h. The infarcted side of the brain had marked elevation of TNF-α gene and protein expression, compared to the sham brain. The expression of CD14, a co-receptor of TLR4, was induced by MCAO, while the expression of TLR4 remained unchanged. The levels of inducible nitric oxide synthase (iNOS) and nitrotyrosine were also upregulated in the infracted side of the brain. Correspondingly, exposing murine microglial BV2 cells to hypoxia (1% O2) for 20h resulted in an increased expression of TNF-α, CD14, iNOS, and nitrotyrosine. When BV2 cells were treated with l-canavanine, an iNOS selective inhibitor, the elevation of TNF-α and CD14 induced by hypoxia was inhibited. This inhibition was associated with an increase of IκB. These results suggest that the upregulation of TNF-α production in ischemic stroke is partially through increasing iNOS, and then CD14 expression leading to the activation of the NF-κB pathway in microglia.
Collapse
Affiliation(s)
- Mian Zhou
- Department of Surgery, Hofstra North Shore-LIJ School of Medicine, The Feinstein Institute for Medical Research, Manhasset, NY 11030, USA
| | | | | | | |
Collapse
|
32
|
Mice lacking the β2 adrenergic receptor have a unique genetic profile before and after focal brain ischaemia. ASN Neuro 2012; 4:AN20110020. [PMID: 22867428 PMCID: PMC3436074 DOI: 10.1042/an20110020] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
The role of the β2AR (β2 adrenergic receptor) after stroke is unclear as pharmacological manipulations of the β2AR have produced contradictory results. We previously showed that mice deficient in the β2AR (β2KO) had smaller infarcts compared with WT (wild-type) mice (FVB) after MCAO (middle cerebral artery occlusion), a model of stroke. To elucidate mechanisms of this neuroprotection, we evaluated changes in gene expression using microarrays comparing differences before and after MCAO, and differences between genotypes. Genes associated with inflammation and cell deaths were enriched after MCAO in both genotypes, and we identified several genes not previously shown to increase following ischaemia (Ccl9, Gem and Prg4). In addition to networks that were similar between genotypes, one network with a central core of GPCR (G-protein-coupled receptor) and including biological functions such as carbohydrate metabolism, small molecule biochemistry and inflammation was identified in FVB mice but not in β2KO mice. Analysis of differences between genotypes revealed 11 genes differentially expressed by genotype both before and after ischaemia. We demonstrate greater Glo1 protein levels and lower Pmaip/Noxa mRNA levels in β2KO mice in both sham and MCAO conditions. As both genes are implicated in NF-κB (nuclear factor κB) signalling, we measured p65 activity and TNFα (tumour necrosis factor α) levels 24 h after MCAO. MCAO-induced p65 activation and post-ischaemic TNFα production were both greater in FVB compared with β2KO mice. These results suggest that loss of β2AR signalling results in a neuroprotective phenotype in part due to decreased NF-κB signalling, decreased inflammation and decreased apoptotic signalling in the brain.
Collapse
|
33
|
Cukras CA, Petrou P, Chew EY, Meyerle CB, Wong WT. Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study. Invest Ophthalmol Vis Sci 2012; 53:3865-74. [PMID: 22589436 DOI: 10.1167/iovs.11-9413] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
PURPOSE Inflammation contributes significantly to the pathogenesis of diabetic macular edema (DME). In particular, retinal microglia demonstrate increased activation and aggregation in areas of DME. Study authors investigated the safety and potential efficacy of oral minocycline, a drug capable of inhibiting microglial activation, in the treatment of DME. METHODS A single-center, prospective, open-label phase I/II clinical trial enrolled five participants with fovea-involving DME who received oral minocycline 100 mg twice daily for 6 months. Main outcome measurements included best-corrected visual acuity (BCVA), central retinal subfield thickness (CST), and central macular volume using spectral domain optical coherence tomography (SD-OCT) and late leakage on fluorescein angiography (FA). RESULTS Findings indicated that the study drug was well tolerated and not associated with significant safety issues. In study eyes, mean BCVA improved continuously from baseline at 1, 2, 4, and 6 months by +1.0, +4.0, +4.0, and +5.8 letters, respectively, while mean retinal thickness (CST) on OCT decreased by -2.9%, -5.7%, -13.9, and -8.1% for the same time points. At month 6, mean area of late leakage on FA decreased by -34.4% in study eyes. Mean changes in contralateral fellow eyes also demonstrated similar trends. Improvements in outcome measures were not correlated with concurrent changes in systemic factors. CONCLUSIONS In this pilot proof-of-concept study of DME, minocycline as primary treatment was associated with improved visual function, central macular edema, and vascular leakage, comparing favorably with historical controls from previous studies. Microglial inhibition with oral minocycline may be a promising therapeutic strategy targeting the inflammatory etiology of DME. (ClinicalTrials.gov number, NCT01120899.).
Collapse
Affiliation(s)
- Catherine A Cukras
- Division of Epidemiology and Clinical Applications, National Institutes of Health, Bethesda, Maryland 20892, USA.
| | | | | | | | | |
Collapse
|
34
|
Wulff H, Castle NA. Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Rev Clin Pharmacol 2012; 3:385-96. [PMID: 22111618 DOI: 10.1586/ecp.10.11] [Citation(s) in RCA: 144] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The Ca(2+)-activated K(+) channel K(Ca)3.1 regulates membrane potential and calcium signaling in erythrocytes, activated T and B cells, macrophages, microglia, vascular endothelium, epithelia, and proliferating vascular smooth muscle cells and fibroblasts. K(Ca)3.1 has therefore been suggested as a potential therapeutic target for diseases such as sickle cell anemia, asthma, coronary restenosis after angioplasty, atherosclerosis, kidney fibrosis and autoimmunity, where activation and excessive proliferation of one or more of these cell types is involved in the pathology. This article will review the physiology and pharmacology of K(Ca)3.1 and critically examine the available preclinical and clinical data validating K(Ca)3.1 as a therapeutic target.
Collapse
|
35
|
The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab 2011; 31:2363-74. [PMID: 21750563 PMCID: PMC3323185 DOI: 10.1038/jcbfm.2011.101] [Citation(s) in RCA: 81] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Microglia and brain infiltrating macrophages significantly contribute to the secondary inflammatory damage in the wake of ischemic stroke. Here, we investigated whether inhibition of KCa3.1 (IKCa1/KCNN4), a calcium-activated K(+) channel that is involved in microglia and macrophage activation and expression of which increases on microglia in the infarcted area, has beneficial effects in a rat model of ischemic stroke. Using an HPLC/MS assay, we first confirmed that our small molecule KCa3.1 blocker TRAM-34 effectively penetrates into the brain and achieves micromolar plasma and brain concentrations after intraperitoneal injection. Then, we subjected male Wistar rats to 90 minutes of middle cerebral artery occlusion (MCAO) and administered either vehicle or TRAM-34 (10 or 40 mg/kg intraperitoneally twice daily) for 7 days starting 12 hours after reperfusion. Both compound doses reduced infarct area by ≈ 50% as determined by hematoxylin & eosin staining on day 7 and the higher dose also significantly improved neurological deficit. We further observed a significant reduction in ED1(+)-activated microglia and TUNEL-positive neurons as well as increases in NeuN(+) neurons in the infarcted hemisphere. Our findings suggest that KCa3.1 blockade constitutes an attractive approach for the treatment of ischemic stroke because it is still effective when initiated 12 hours after the insult.
Collapse
|
36
|
Andrews JA, Neises KD. Cells, biomarkers, and post-traumatic stress disorder: evidence for peripheral involvement in a central disease. J Neurochem 2011; 120:26-36. [PMID: 22017326 DOI: 10.1111/j.1471-4159.2011.07545.x] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Post-traumatic stress disorder (PTSD) is a complicated CNS syndrome. Looking beyond the CNS, recent studies suggest that peripheral blood mononuclear cells could cause and/or exacerbate PTSD. This review summarizes the literature, describes associations between circulating peripheral blood cells and PTSD, proposes a novel mechanism, and analyzes several biomarkers that appear to associate with PTSD symptoms. Several experimental animal models have shown that peripheral blood mononuclear cell activity can cause hippocampal volume loss and PTSD-like symptoms. Data from these models suggest that a traumatic event and/or traumatic events can trigger peripheral cells to migrate, mediate inflammation, and decrease neurogenesis, potentially leading to CNS volume loss. Biomarkers that associate with PTSD symptoms have the potential to differentiate PTSD from traumatic brain injury, but more work needs to be done. Research examining the mechanism of how traumatic events are linked to peripheral blood mononuclear cell functions and biomarkers may offer improved diagnoses and treatments for PTSD patients.
Collapse
Affiliation(s)
- James A Andrews
- Naval Health Research Center, San Diego, California 92106-3521, USA.
| | | |
Collapse
|
37
|
Yin Y, Li G. Hypoxia induces T Helper 17 cell upregulation in cultured peripheral blood mononuclear cells from chronic stage patients of severe cerebral infarction. Microbiol Immunol 2011; 55:130-4. [PMID: 21204953 DOI: 10.1111/j.1348-0421.2010.00301.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Studies have shown the IL-17A involvement in human ischemic stroke patients in vivo. Whether the IL-17A expression was originated from Th17 and could be stimulated by hypoxia remained unknown. Here we report the Th17 upregulation in anaerobic cultured PBMC from chronic stage patients of severe cerebral infarction. By using ELISA and FACS we examined IL-1β, IFN-γ, IL-23 and IL-17A protein levels in the supernatants and Th1/Th17 ratios in PBMC. Statistical significance of Th17 but not Th1 upregulation was proved in 6-hr anaerobic cultured patient groups (P < 0.001). Hence, Th17 might be essential in the autoimmune pathogenesis when hypoxia recurs in severe ischemic stroke patients.
Collapse
Affiliation(s)
- YanHong Yin
- Department of Neurology, Chinese People Liberation Army (PLA) General Hospital, 28 Fuxing Road, Haidian District, Beijing 100854, China.
| | | |
Collapse
|
38
|
Pluta R, Ułamek M, Jabłoński M. Alzheimer's mechanisms in ischemic brain degeneration. Anat Rec (Hoboken) 2010; 292:1863-81. [PMID: 19943340 DOI: 10.1002/ar.21018] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
There is increasing evidence for influence of Alzheimer's proteins and neuropathology on ischemic brain injury. This review investigates the relationships between beta-amyloid peptide, apolipoproteins, presenilins, tau protein, alpha-synuclein, inflammation factors, and neuronal survival/death decisions in brain following ischemic episode. The interactions of these molecules and influence on beta-amyloid peptide synthesis and contribution to ischemic brain degeneration and finally to dementia are reviewed. Generation and deposition of beta-amyloid peptide and tau protein pathology are important key players involved in mechanisms in ischemic neurodegeneration as well as in Alzheimer's disease. Current evidence suggests that inflammatory process represents next component, which significantly contribute to degeneration progression. Although inflammation was initially thought to arise secondary to ischemic neurodegeneration, recent studies present that inflammatory mediators may stimulate amyloid precursor protein metabolism by upregulation of beta-secretase and therefore are able to establish a vicious cycle. Functional brain recovery after ischemic lesion was delayed and incomplete by an injury-related increase in the amount of the neurotoxic C-terminal of amyloid precursor protein and beta-amyloid peptide. Moreover, ischemic neurodegeneration is strongly accelerated with aging, too. New therapeutic alternatives targeting these proteins and repairing related neuronal changes are under development for the treatment of ischemic brain consequences including memory loss prevention.
Collapse
Affiliation(s)
- Ryszard Pluta
- Laboratory of Ischemic and Neurodegenerative Brain Research, Department of Neurodegenerative Disorders, Mossakowski Medical Research Centre, Polish Academy of Sciences, Pawinskiego 5 Str., Warsaw, Poland.
| | | | | |
Collapse
|
39
|
Kassner S, Kollmar R, Bonaterra G, Hildebrandt W, Schwab S, Kinscherf R. The early immunological response to acute ischemic stroke: Differential gene expression in subpopulations of mononuclear cells. Neuroscience 2009; 160:394-401. [DOI: 10.1016/j.neuroscience.2009.02.050] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2008] [Revised: 01/28/2009] [Accepted: 02/22/2009] [Indexed: 11/16/2022]
|
40
|
Parney IF, Waldron JS, Parsa AT. Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. J Neurosurg 2009; 110:572-82. [PMID: 19199469 DOI: 10.3171/2008.7.jns08475] [Citation(s) in RCA: 120] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECT To date, glioma immunotherapy has been focused mostly on stimulating antitumor peripheral lymphocyte responses; however, some data suggest that microglia and/or macrophages (not lymphocytes) are the predominant inflammatory cells infiltrating gliomas. To study this hypothesis further, the authors analyzed inflammatory cell infiltrates in fresh human malignant glioma specimens and primary cultures. METHODS Single-cell suspensions from fresh operative malignant glioma specimens, obtained by stereotactic localization, were analyzed for CD11b and CD45 by using flow cytometry. A comparison was made with peripheral blood mononuclear cells. In a subset of patients, a more detailed flow cytometry analysis of Class I and II major histocompatibility complex, B7-1, B7-2, CD11c, and CD14 expression was performed. Macrophage-like cells in primary glioma cultures were similarly assessed. RESULTS Operative samples were obtained from 9 newly diagnosed malignant gliomas. The mean percent of CD45(+)/CD11b(-) cells (lymphocytes) was 2.48% (range 0.65-5.50%); CD45(dim)/CD11b(+) cells (microglia), 1.65% (range 0.37-3.92%); and CD45(bright)/CD11b+ (monocytes/macrophages), 6.25% (range 1.56-15.3%). More detailed fluorescence-activated cell sorting suggested that macrophage-like cells expressed Class I and II major histocompatibility complex, B7-2, and CD11c but not CD14 or B7-1. Primary human glioma cultures contained significant numbers of macrophage-like (CD45(bright)/CD11b(+)) cells, but these cells were lost with successive passages. These cells maintained the immunomarker profiles of macrophage-like cells from fresh specimens only if they were cultured in serum-free media. CONCLUSIONS The CD45(+)/CD11b(+) cells are the predominant inflammatory cell infiltrating human gliomas. Of this type, the CD45(bright)/CD11b(+) cells, a phenotype compatible with circulating macrophages in rodent models, and not microglia, are the most common. Their immunomarker profile is compatible with an immature antigen-presenting cell. They are present in primary glioma cultures but are lost in successive passages. Their role is enigmatic, and they may prove an important target for future glioma immunotherapy studies.
Collapse
Affiliation(s)
- Ian F Parney
- Department of Clinical Neurosciences, Southern Alberta Cancer Research Institute, and Hotchkiss Brain Institute, University of Calgary, Alberta, Canada
| | | | | |
Collapse
|
41
|
Abstract
Innate pattern recognition receptors are implicated in first-line defense against pathogens but also participate in maintenance of tissue homeostasis and response to injury. This chapter reviews the role of Toll-like receptors (TLRs) in neuronal and glial responses that are associated with neurodegeneration. Accompanying roles for infection and inflammation, involvement in clinical neurodegenerative disorders, and heterogeneity of glial response are discussed. A "strength of signal" hypothesis is advanced in an attempt to reconcile evolutionarily selected and therefore likely beneficial effects of TLR signaling in the nervous system with capability for neurotoxocity and gliotoxicity.
Collapse
Affiliation(s)
- Trevor Owens
- Medical Biotechnology Center, University of Southern Denmark, Winsloewparken 25, 5000, Odense C, Denmark.
| |
Collapse
|
42
|
Degos V, Teissier N, Gressens P, Puybasset L, Mantz J. [Inflammation and acute brain injuries in intensive care]. ACTA ACUST UNITED AC 2008; 27:1008-15. [PMID: 19010639 DOI: 10.1016/j.annfar.2008.07.099] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2008] [Accepted: 07/17/2008] [Indexed: 11/26/2022]
Abstract
Patients with acute brain injuries or susceptibility to post-surgery stroke are a major therapeutic challenge for intensive care and anaesthesiology medicine. The control of systemic stress involved in brain damage is necessary to reduce the frequency and severity of secondary brain lesions. Inflammation is known to be directly involved in acute brain lesions. The brain is a major participant in inflammation control through activation or inhibition effects. The exact mechanisms involved in deleterious effects following acute brain injuries due to inflammation are still unknown. This non-exhaustive study will expose the principal processes involved in inflammatory brain disease and explain the consequences of peripheral inflammation for the brain. Neuroprotection strategies in acute neuroinflammation will be reported with a focus on anaesthetic agents and the inflammation cascade.
Collapse
Affiliation(s)
- V Degos
- Unité Inserm U676, hôpital Robert-Debré, 48, boulevard Serrurier, 75019 Paris, France.
| | | | | | | | | |
Collapse
|
43
|
Acute neurodegeneration and the inflammasome: central processor for danger signals and the inflammatory response? J Cereb Blood Flow Metab 2008; 28:867-81. [PMID: 18212795 DOI: 10.1038/sj.jcbfm.9600609] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Activation of the inflammatory response is a crucial event in the adverse outcome of cerebral ischemia, which is promoted by proinflammatory cytokines such as interleukin (IL)-1beta. Although caspase-1 is necessary for IL-1beta processing, the 'upstream' signaling pathways were, until recently, essentially unknown. Fortunately, the inflammasome, a multiprotein complex responsible for activating caspase-1 and caspase-5, has recently been characterized. The activation of the inflammasome can result in one of several consequences such as cytokine secretion, cell death, or the development of a stress-resistant state. The significance of the inflammasome for the initiation of the inflammatory response during systemic diseases has already been shown and members of the inflammasome complex were recently found to be induced in acute brain injury. However, the specific pathophysiologic role of the inflammasome in neurodegenerative disorders still remains to be clarified. The underlying theories (e.g., danger signal theory) along with the signaling pathways that link the inflammasome to acute neurodegeneration will be discussed here. Furthermore, the stimuli that potentially activate the inflammasome in cerebral ischemia will be specified, as well as their relation to well-known pathways activating the innate immune response (e.g., Toll-like receptor signaling) and the consequences that result from their activation (beneficial versus deleterious).
Collapse
|
44
|
Kim JS, Romero R, Kim MR, Kim YM, Friel L, Espinoza J, Kim CJ. Involvement of Hofbauer cells and maternal T cells in villitis of unknown aetiology. Histopathology 2008; 52:457-64. [PMID: 18315598 DOI: 10.1111/j.1365-2559.2008.02964.x] [Citation(s) in RCA: 118] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
AIMS The nature of villitis of unknown aetiology (VUE) is intriguing in terms of its aetiology, origin of inflammatory cells and immunophenotype of T cells involved. The aim was to determine the origin of macrophages and the immunophenotype of T lymphocytes in VUE associated with various complications of pregnancy. METHODS AND RESULTS Placentas with VUE (n = 45) were studied by chromogenic in-situ hybridization (CISH) for Y chromosome (DYZ1) and immunohistochemistry for CD14, CD68, Ki67 (n = 10; all from male neonates) and a panel of T-cell antigens (CD3, CD4 and CD8) (n = 35). All of the placentas from male neonates showed CISH+ signals from Y chromosomes in the majority of macrophages, but not in lymphocytes, indicating that the macrophages were of fetal origin. Many macrophages of the affected chorionic villi were Ki67+, suggesting that they are hyperplastic Hofbauer cells. Among the lymphocytes, CD8+ T cells outnumbered CD4+ T cells in all placentas with different obstetrical conditions. CONCLUSIONS We define primary components of VUE as maternal CD8+ T cells and hyperplastic Hofbauer cells. We propose that VUE is a unique inflammatory reaction where the leucocytes from two hosts are key partners, analogous to either allograft rejection or graft-versus-host disease.
Collapse
Affiliation(s)
- J-S Kim
- Perinatology Research Branch, NICHD/NIH/DHHS, Bethesda, MD, USA
| | | | | | | | | | | | | |
Collapse
|
45
|
Rojas S, Martín A, Arranz MJ, Pareto D, Purroy J, Verdaguer E, Llop J, Gómez V, Gispert JD, Millán O, Chamorro A, Planas AM. Imaging brain inflammation with [(11)C]PK11195 by PET and induction of the peripheral-type benzodiazepine receptor after transient focal ischemia in rats. J Cereb Blood Flow Metab 2007; 27:1975-86. [PMID: 17457364 DOI: 10.1038/sj.jcbfm.9600500] [Citation(s) in RCA: 120] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
[(11)C]PK11195 is used in positron emission tomography (PET) studies for imaging brain inflammation in vivo as it binds to the peripheral-type benzodiazepine receptor (PBR) expressed by reactive glia and macrophages. However, features of the cellular reaction required to induce a positive [(11)C]PK11195 signal are not well characterized. We performed [(11)C]PK11195 PET and autoradiography in rats after transient focal cerebral ischemia. We determined [(3)H]PK11195 binding and PBR expression in brain tissue and examined the lesion with several markers. [(11)C]PK11195 standard uptake value increased at day 4 and grew further at day 7 within the ischemic core. Accordingly, ex vivo [(3)H]PK11195 binding increased at day 4, and increases further at day 7. The PET signal also augmented in peripheral regions, but to a lesser extent than in the core. Binding in the region surrounding infarction was supported by [(11)C]PK11195 autoradiography at day 7 showing that the radioactive signal extended beyond the infarcted core. Enhanced binding was preceded by increases in PBR mRNA expression in the ipsilateral hemisphere, and a 18-kDa band corresponding to PBR protein was detected. Peripheral-type benzodiazepine receptor immunohistochemistry showed subsets of ameboid microglia/macrophages within the infarcted core showing a distinctive strong PBR expression from day 4. These cells were often located surrounding microhemorrhages. Reactive astrocytes forming a rim surrounding infarction at day 7 also showed some PBR immunostaining. These results show cellular heterogeneity in the level of PBR expression, supporting that PBR is not a simple marker of inflammation, and that the extent of [(11)C]PK11195 binding depends on intrinsic features of the inflammatory cells.
Collapse
Affiliation(s)
- Santiago Rojas
- Department of Brain Ischemia and Neurodegeneration, Institut d'Investigacions Biomèdiques de Barcelona (IIBB)-Consejo Superior de Investigaciones Científicas (CSIC), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol 2007; 184:53-68. [PMID: 17188755 PMCID: PMC1868538 DOI: 10.1016/j.jneuroim.2006.11.014] [Citation(s) in RCA: 888] [Impact Index Per Article: 52.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2006] [Accepted: 11/17/2006] [Indexed: 12/17/2022]
Abstract
Recent works in the area of stroke and brain ischemia has demonstrated the significance of the inflammatory response accompanying necrotic brain injury. Acutely, this response appears to contribute to ischemic pathology, and anti-inflammatory strategies have become popular. This chapter will discuss the current knowledge of the contribution of systemic and local inflammation in experimental stroke. It will review the role of specific cell types including leukocytes, endothelium, glia, microglia, the extracellular matrix and neurons. Intracellular inflammatory signaling pathways such as nuclear factor kappa beta and mitogen-activated protein kinases, and mediators produced by inflammatory cells such as cytokines, chemokines, reactive oxygen species and arachidonic acid metabolites will be reviewed as well as the potential for therapy in stroke and hypoxic-ischemic injury.
Collapse
Affiliation(s)
- Qing Wang
- Department of Neurology, University of California, San Francisco and the San Francisco Veterans Affairs Medical Center, San Francisco, CA
- Department of Anesthesia, Stanford University School of Medicine, Stanford, CA
| | - Xian Nan Tang
- Department of Neurology, University of California, San Francisco and the San Francisco Veterans Affairs Medical Center, San Francisco, CA
- Department of Anesthesia, Stanford University School of Medicine, Stanford, CA
| | - Midori A. Yenari
- Department of Neurology, University of California, San Francisco and the San Francisco Veterans Affairs Medical Center, San Francisco, CA
| |
Collapse
|
47
|
Abstract
This chapter will discuss the current knowledge of the contribution of systemic and local inflammation in acute and sub-chronic stages of experimental stroke in both the adult and neonate. It will review the role of specific cell types and interactions among blood cells, endothelium, glia, microglia, the extracellular matrix and neurons - cumulatively called "neurovascular unit" - in stroke induction and evolution. Intracellular inflammatory signaling pathways such as nuclear factor kappa beta and mitogen-activated protein kinases, and mediators produced by inflammatory cells such as cytokines, chemokines, reactive oxygen species and arachidonic acid metabolites, as well as the modifying role of age on these mechanisms, will be reviewed as well as the potential for therapy in stroke and hypoxic-ischemic injury.
Collapse
|
48
|
Tang Y, Xu H, Du X, Lit L, Walker W, Lu A, Ran R, Gregg JP, Reilly M, Pancioli A, Khoury JC, Sauerbeck LR, Carrozzella JA, Spilker J, Clark J, Wagner KR, Jauch EC, Chang DJ, Verro P, Broderick JP, Sharp FR. Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J Cereb Blood Flow Metab 2006; 26:1089-102. [PMID: 16395289 DOI: 10.1038/sj.jcbfm.9600264] [Citation(s) in RCA: 234] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Ischemic brain and peripheral white blood cells release cytokines, chemokines and other molecules that activate the peripheral white blood cells after stroke. To assess gene expression in these peripheral white blood cells, whole blood was examined using oligonucleotide microarrays in 15 patients at 2.4+/-0.5, 5 and 24 h after onset of ischemic stroke and compared with control blood samples. The 2.4-h blood samples were drawn before patients were treated either with tissue-type plasminogen activator (tPA) alone or with tPA plus Eptifibatide (the Combination approach to Lysis utilizing Eptifibatide And Recombinant tPA trial). Most genes induced in whole blood at 2 to 3 h were also induced at 5 and 24 h. Separate studies showed that the genes induced at 2 to 24 h after stroke were expressed mainly by polymorphonuclear leukocytes and to a lesser degree by monocytes. These genes included: matrix metalloproteinase 9; S100 calcium-binding proteins P, A12 and A9; coagulation factor V; arginase I; carbonic anhydrase IV; lymphocyte antigen 96 (cluster of differentiation (CD)96); monocarboxylic acid transporter (6); ets-2 (erythroblastosis virus E26 oncogene homolog 2); homeobox gene Hox 1.11; cytoskeleton-associated protein 4; N-formylpeptide receptor; ribonuclease-2; N-acetylneuraminate pyruvate lyase; BCL6; glycogen phosphorylase. The fold change of these genes varied from 1.6 to 6.8 and these 18 genes correctly classified 10/15 patients at 2.4 h, 13/15 patients at 5 h and 15/15 patients at 24 h after stroke. These data provide insights into the inflammatory responses after stroke in humans, and should be helpful in diagnosis, understanding etiology and pathogenesis, and guiding acute treatment and development of new treatments for stroke.
Collapse
Affiliation(s)
- Yang Tang
- MIND Institute and Department of Neurology, University of California at Davis, Sacramento, California 95817, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Cosenza MA, Lee SC. Author's Response. Brain Pathol 2006. [DOI: 10.1111/j.1750-3639.2003.tb00024.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
50
|
Beschorner R. Correspondence. Brain Pathol 2006. [DOI: 10.1111/j.1750-3639.2003.tb00023.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|